Compounds and Uses Thereof

Abstract

This invention relates to novel compounds having the structural formula I below: and their pharmaceutically acceptable salts, tautomers or in vivo-hydrolysable precursors, compositions and methods of use thereof. These novel compounds provide a treatment or prophylaxis of anxiety disorders, cognitive disorders, and/or mood disorders.

1 . A compound selected from 4-amino-8-(2-fluoro-6-methoxy-phenyl)-N-propylcinnoline-3-carboxamide and pharmaceutically acceptable salts thereof. 
   
   
       2 . A method of treating or preventing an anxiety disorder in a mammal, comprising administering to the mammal a therapeutically effective amount of a compound of  claim 1 . 
   
   
       3 . The method of  claim 2  wherein the anxiety disorder is panic disorder, panic disorder without agoraphobia, panic disorder with agoraphobia, agoraphobia without history of panic disorder, specific phobia, social phobia, social anxiety disorder, obsessive-compulsive disorder, posttraumatic stress disorder, acute stress disorder, generalized anxiety disorder, or generalized anxiety disorder due to a general medical condition. 
   
   
       4 . The method of  claim 2  wherein the mammal is a human. 
   
   
       5 . A method of treating or preventing an anxiety disorder in a mammal, comprising administering to the mammal a therapeutically effective amount of a compound of  claim 1  and at least one cognitive enhancing agent, memory enhancing agent, or choline esterase inhibitor. 
   
   
       6 . The method of  claim 5  wherein the anxiety disorder is panic disorder, panic disorder without agoraphobia, panic disorder with agoraphobia, agoraphobia without history of panic disorder, specific phobia, social phobia, social anxiety disorder, obsessive-compulsive disorder, posttraumatic stress disorder, acute stress disorder, generalized anxiety disorder, or generalized anxiety disorder due to a general medical condition. 
   
   
       7 . The method of  claim 5  wherein the mammal is a human. 
   
   
       8 . A method of treating or preventing a cognitive disorder in a mammal, comprising administering to the mammal a therapeutically effective amount of a compound of  claim 1 . 
   
   
       9 . The method of  claim 8  wherein the cognitive disorder is Alzheimer's disease, dementia, dementia due to Alzheimer's disease, or dementia due to Parkinson's disease. 
   
   
       10 . The method of  claim 8  wherein the mammal is a human. 
   
   
       11 . A method of treating or preventing a cognitive disorder in a mammal, comprising administering to the mammal a therapeutically effective amount of a compound of  claim 1  and at least one cognitive enhancing agent, memory enhancing agent, or choline esterase inhibitor. 
   
   
       12 . The method of  11  wherein the cognitive disorder is Alzheimer's disease, dementia, dementia due to Alzheimer's disease, or dementia due to Parkinson's disease. 
   
   
       13 . The method of  claim 11  wherein the mammal is a human. 
   
   
       14 . A method of treating or preventing a mood disorder in a mammal, comprising administering to the mammal a therapeutically effective amount of a compound of  claim 1 . 
   
   
       15 . The method of  claim 14  wherein the mood disorder is a depressive disorder. 
   
   
       16 . The method of  claim 15  wherein the depressive disorder is major depressive disorder, dysthymic disorder, bipolar depression and/or bipolar mania, bipolar I with or without manic, depressive or mixed episodes, bipolar II, cyclothymic disorder, mood disorder due to a general medical condition, manic episodes associated with bipolar disorder, or mixed episodes associated with bipolar disorder. 
   
   
       17 . The method of  claim 14  wherein the mammal is a human. 
   
   
       18 . A method of treating or preventing a mood disorder in a mammal, comprising administering to the mammal a therapeutically effective amount of a compound of  claim 1  and at least one cognitive enhancing agent, memory enhancing agent, or choline esterase inhibitor. 
   
   
       19 . The method of  claim 18  wherein the mood disorder is a depressive disorder. 
   
   
       20 . The method of  claim 19  wherein the depressive disorder is major depressive disorder, dysthymic disorder, bipolar depression and/or bipolar mania, bipolar I with or without manic, depressive or mixed episodes, bipolar II, cyclothymic disorder, mood disorder due to a general medical condition, manic episodes associated with bipolar disorder, or mixed episodes associated with bipolar disorder. 
   
   
       21 . The method of  claim 19  wherein the mammal is a human. 
   
   
       22 . An atropisomer of a compound according to  claim 1 .